Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.01 (-0.32%)

    Market Cap: $10.17M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    27%(4/15)
    Avg Surprise
    -52.97%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.77
    Range-$1.09 - -$0.21
    7 analysts
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.51
    Range-$0.81 - -$0.21
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago-$0.510.0%
    30d ago-$0.510.0%
    7d ago-$0.510.0%
    Current-$0.51
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-161.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.68xQuick Ratio3.68x
    Trading Statistics
    Beta3.04Avg Volume13.37K
    52-Week High$15.0052-Week Low$2.80

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 12.6% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 41.5, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$3.17
    SMA 20$3.23
    SMA 50$3.51
    SMA 200$4.86
    EMA 10$3.16
    EMA 20$3.24
    EMA 50$3.50
    EMA 200$4.96

    MACD

    Line: -0.12Signal: -0.12Hist: -0.00

    ADX

    ADX: 16.1+DI: 12.9-DI: 23.5

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down80.0
    PSAR$3.47

    Bollinger Bands

    Upper Band$3.51
    Lower Band$2.95
    %B Position1747%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    41.5

    Momentum Oscillators

    Stoch %K36.5
    Stoch %D42.7
    Williams %R-65.2
    ROC (10d)-10.5%
    Momentum-0.36
    CCI (20d)-103.1
    MFI (14d)48.5

    Volatility Measures

    ATR (14d)$0.28(9.1%)
    StdDev (20d)0.14
    Hist Vol65.4%(High)

    Volume Flow

    VWAP$3.05
    OBV1.1B
    AD Line394.9B
    CMF (20d)0.240

    Volume Metrics

    Avg Vol (20d)13.7K
    Vol Ratio0.3x(Low)
    VWMA (20d)$3.17

    Pivot Points

    R3$3.31
    R2$3.20
    R1$3.14
    Pivot Point$3.03
    S1$2.97
    S2$2.86
    S3$2.80

    Advanced Oscillators

    TSI-15.15
    Ultimate Osc55.4
    KST-90.41

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about INTS

    News

    INTS Valuation

    INTS Profitability: Margins, ROIC and FCF

    Intensity Therapeutics, Inc. Common stock (INTS) has an operating margin of 0.0% and a net margin of 0.0%.

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -161.8%
    INTS financial statements

    Intensity Therapeutics, Inc. Common stock Competitors

    The companies most similar to Intensity Therapeutics, Inc. Common stock (INTS) include Marker Therapeutics, Tempest Therapeutics and Tscan Therapeutics.

    Sector: Healthcare

    Companies most similar to Intensity Therapeutics, Inc. Common stock

    INTS Analyst Ratings

    Intensity Therapeutics, Inc. Common stock (INTS) has a Buy consensus from 6 analysts: 6 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    0
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0
    INTS stock forecast

    INTS Bull Case vs Bear Case

    Bull case

    • 100.0% of INTS's analyst ratings are Buy or Strong Buy.

    Bear case

    • INTS beat EPS estimates in 37.5% of its last 8 reported quarters.

    INTS Earnings: Beat Rate and Next Report

    Intensity Therapeutics, Inc. Common stock (INTS) beat the EPS estimate in 3 of the last 8 quarters (37.5%).

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -65.0%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.77
    INTS earnings history

    INTS Earnings Call

    The latest INTS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About INTS

    Does INTS pay dividends?

    Intensity Therapeutics, Inc. Common stock (INTS) does not currently pay a regular dividend.

    What is INTS's market cap?

    Intensity Therapeutics, Inc. Common stock (INTS) has a market capitalization of $10.17M with a current stock price of $3.07.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.